Arcellx

Kite, a Gilead Company, will present 18 studies at the 66th ASH Annual Meeting, showcasing CAR T-cell therapy's efficacy in blood cancers. Key highlights include durable responses and manageable safety profiles for anito-cel in relapsed/refractory multiple myeloma, long-term survival data for Yescarta and Tecartus in various blood cancers, and advancements in next-generation CAR T-cell therapies like KITE-753.

2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.

The global cell and gene therapy clinical trials market was valued at USD 11.62 billion in 2023 and is projected to reach USD 47.40 billion by 2033, growing at a CAGR of 15.09%. Factors driving growth include a favorable regulatory environment, increasing interest in cancer treatments, patient demand for innovative therapies, and rising R&D funding. North America leads with a 49.76% share, while Asia Pacific is expected to grow fastest at a CAGR of 15.7%. The oncology segment dominates with a 49.1% share.

Kite and Arcellx announced a Phase III trial, iMMagine-3, for anito-cel, a BCMA CAR T-cell therapy targeting relapsed/refractory multiple myeloma. The global study will enroll 450 adults across 130 sites, assessing efficacy and safety against standard care. Kite plans to start the trial in late 2024, leveraging its manufacturing expertise for anito-cel's development and commercialization.